A Randomized Phase II Trial Investigating Stereotactic Body RadioTherapy (SBRT) for Prostate Boost Irradiation in the Treatment of High Risk Prostate Cancer (PrCa)
A randomized controlled open-label trial in patients with high risk prostate cancer. Eligible and consenting patients will be randomly allocated to receive stereotactic body radiation therapy (SBRT) boost to prostate or conventional radiation therapy boost to prostate in 1:1 ratio. Prostate radiation therapy boost will be administered after standard pelvic radiation therapy. Subjects will be followed for 24 months post radiation treatment for Quality of Life assessment and toxicity.
Primary Outcome:
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the Canadian Cancer Society